Treatment with an ACE inhibitor drug was as effective in reducing deaths, heart attacks and stroke in a high-risk group of patients as a newer and more expensive angiotensin-receptor blocker (ARB) drug, a large international study has found.
The study of more than 17,000 people with coronary artery disease or diabetes found no …
New scientific approaches for the prevention and acute treatment of stroke were the focus at the 12th European Stroke Conference in Valencia, Spain, last week. During the symposium and subsequent press conference, Germany’s Boehringer Ingelheim presented its comprehensive cerebrovascular protection program for acute and secondary stroke.
Most Popular
10 Jobs That Pay $30 An Hour
Public Speaking: 7 Secrets Of Great Public Speakers
…
CHICAGO (AFP) — A new drug for treating high blood pressure, telmisartan, is as effective as the popular drug ramipril but with fewer side effects, according to a study published Monday.
After four and a half years of study, researchers found that temisartan (marketed as Micardis, Pritor or Kinzal) and ramipril (Trita…
Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, April 16 (DDMAC). A journal ad and a sales aid for Micardis (telmisartan) tablets, submitted via Form 2253, were deemed misleading for implying superiority over other angiotensin II receptor blockers, insufficient contextual information for a pie chart and a graph that presented clinical data inaccurately.
Most Popular
Public Speaking: 7 Secrets Of Great Public Speakers
10 Jobs That Pay $30 A…
(Full text of statement. Contact details below.)
PHOENIX, Ariz., Feb 14 PRNewswire-AsiaNet - Today, in Phoenix, USA, Boehringer Ingelheim announced PRoFESS, the world’s largest-ever study in second stroke prevention. PRoFESS (Prevention Reg…
Boehringer Ingelheim Pharmaceuticals Inc. has received clearance from the Food and Drug Administration to market Micardis (telmisartan), a once-daily angiotensin II receptor blocker for the treatment of hypertension. Data from placebocontrolled trials involving 1,455 patients for up to 12 weeks demonstrated that Micardis controlled blood pressure in up to 65 percent of patie…
Yes. The angiotensin-converting enzyme inhibitor (ACEI) ramipril and the angiotensin receptor blocker (ARB) telmisartan are equally effective for secondary cardiovascular prevention. The combination of both drugs is no more effective and causes more adverse effects at greater cost.
ACEIs …
Abbott Laboratories will sell and promote Boehringer Ingelheim products in the U.S. under an eight-year co-marketing agreement signed by the two companies. The Boehringer products are Micardis (telmisartan), an angiotension II receptor blocker for the treatment…
